$256 Million is the total value of Cavalier Investments, LLC's 93 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
New | SIMPLIFY EXCHANGE TRADED FUNmulti qis altern | $5,940,696 | – | 229,038 | +100.0% | 2.32% | – | |
XLC | New | SELECT SECTOR SPDR TR | $1,888,154 | – | 28,796 | +100.0% | 0.74% | – |
PSX | New | PHILLIPS 66 | $1,814,866 | – | 15,105 | +100.0% | 0.71% | – |
XOM | New | EXXON MOBIL CORP | $1,761,936 | – | 14,985 | +100.0% | 0.69% | – |
MPC | New | MARATHON PETE CORP | $1,523,994 | – | 10,070 | +100.0% | 0.60% | – |
WST | New | WEST PHARMACEUTICAL SVSC INC | $1,511,346 | – | 4,028 | +100.0% | 0.59% | – |
T | New | AT&T INC | $1,498,846 | – | 99,790 | +100.0% | 0.59% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-10-23
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
TECHNOLOGY SELECT SECTOR SPDR FUND | 31 | Q3 2023 | 11.7% |
SELECT SECTOR SPDR TR | 28 | Q3 2023 | 9.1% |
Standard & Poor's Depositary Receipts | 28 | Q3 2023 | 8.2% |
ISHARES TRUST | 28 | Q1 2023 | 3.0% |
SELECT SECTOR SPDR TR | 26 | Q3 2023 | 8.8% |
ISHARES U.S. MEDICAL DEVICES ETF | 26 | Q3 2023 | 4.7% |
ISHARES TRUST | 25 | Q1 2023 | 8.8% |
SELECT SECTOR SPDR TR | 23 | Q3 2023 | 9.1% |
ISHARES TRUST | 22 | Q1 2023 | 2.3% |
SELECT SECTOR SPDR TR | 21 | Q2 2023 | 17.1% |
View Cavalier Investments, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-04-26 |
13F-HR | 2024-02-13 |
13F-HR | 2023-10-23 |
13F-HR | 2023-08-11 |
13F-HR | 2023-05-10 |
13F-HR | 2023-02-10 |
13F-HR | 2022-11-10 |
13F-HR | 2022-08-04 |
13F-HR | 2022-05-04 |
13F-HR | 2022-02-02 |
View Cavalier Investments, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.